FDA Delays Stoke’s Fast-Track Filing for Epilepsy Drug Zorevunersen

Stoke Therapeutics announced that the Food and Drug Administration (FDA) has deferred its request for an expedited filing of zorevunersen, a treatment for severe epilepsy, specifically targeting Dravet syndrome. During a meeting in December, regulatory officials did not completely reject the possibility of Stoke submitting its application later this year. This approach would allow the company to bypass the completion of an ongoing Phase 3 study, which is not expected to conclude until mid-2027.

In an interview, Stoke CEO Ian Smith conveyed that the FDA has requested additional information prior to any decision on the regulatory path for zorevunersen. This feedback suggests that while the agency has concerns, it remains open to further negotiations. Stoke plans to evaluate its options and aims to reach a decision regarding the drug’s regulatory strategy by mid-2024.

The company’s treatment, zorevunersen, has garnered attention due to its potential to address the severe challenges faced by patients suffering from Dravet syndrome, a rare and catastrophic form of epilepsy. Stoke’s ongoing Phase 3 study is crucial for confirming the drug’s efficacy and safety profile, but the timeline for its completion represents a significant hurdle for the company.

Stoke is based in San Francisco and has been at the forefront of developing innovative therapies aimed at treating genetic diseases. The FDA’s response to Stoke’s request reflects the agency’s careful approach to ensuring that new treatments meet stringent safety and effectiveness standards before they can be made available to patients.

As discussions continue between Stoke Therapeutics and the FDA, the outcome may have profound implications for patients and families affected by Dravet syndrome, who are in dire need of effective treatment options. The company remains committed to advancing zorevunersen and hopes to provide updates on its regulatory strategy in the coming months.